PT-141

PT-141, the research name for bremelanotide, is a cyclic heptapeptide with a molecular weight of 1025.18 Da and the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH. Its development traces back to alpha-melanocyte-stimulating hormone (α-MSH) and later to the synthetic analog melanotan II, a compound originally studied for its tanning properties. Researchers noticed that melanotan II produced spontaneous erections in male volunteers during early trials — an unexpected finding that redirected a line of peptide research toward sexual medicine. Palatin Technologies subsequently refined the scaffold, removing the cyclic lactam's direct tanning activity while preserving its ability to activate melanocortin receptors in the brain, ultimately producing PT-141.

What makes PT-141 scientifically interesting is its central mechanism of action. Nearly all existing pharmacological treatments for erectile dysfunction work peripherally, dilating blood vessels to increase genital blood flow. PT-141 instead targets the central nervous system, stimulating pathways that generate sexual arousal at the neurological level. This makes it potentially useful in populations where vascular-acting drugs are insufficient — particularly patients who have failed phosphodiesterase-5 inhibitor therapy.

Research in the early 2000s established the pharmacokinetic and pharmacodynamic profile of subcutaneous PT-141 in healthy men and in men with inadequate responses to sildenafil, as reported in a 2004 study in the International Journal of Impotence Research. A 2005 study in Urology further examined co-administration of intranasal PT-141 with low-dose sildenafil, finding an enhanced erectile response compared to either agent alone.

PT-141's development path ultimately focused on female hypoactive sexual desire disorder (HSDD), a condition defined by persistent low sexual desire causing personal distress, for which no approved pharmacological treatment existed in the United States at the time. The FDA approved bremelanotide (marketed as Vyleesi) in June 2019 for premenopausal women with acquired, generalized HSDD. This approval marked PT-141 as one of a small number of pharmacological agents specifically approved for female sexual dysfunction, and it remains an area of ongoing clinical and mechanistic inquiry.

PT-141 is a cyclic heptapeptide agonist of the melanocortin receptor system. The melanocortin system comprises five G protein-coupled receptors (MC1R through MC5R) that mediate a wide range of physiological functions including pigmentation, energy balance, inflammation, and sexual behavior. PT-141 has demonstrated selective agonist activity at MC3R and MC4R, with MC4R activity considered the primary driver of its pro-sexual effects.

MC4R is expressed in hypothalamic nuclei, including the paraventricular nucleus (PVN), an area known to integrate hormonal and neural signals regulating sexual arousal and behavior. When PT-141 binds MC4R in the PVN, it activates adenylyl cyclase through coupling with Gs proteins, increasing cyclic adenosine monophosphate (cAMP) concentrations. This signaling cascade ultimately increases the activity of oxytocin-producing neurons, and oxytocin release from the PVN contributes to the facilitation of sexual arousal in both male and female animal models.

In males, this central activation promotes erection through a neural rather than vascular pathway. While phosphodiesterase-5 inhibitors block the breakdown of cyclic guanosine monophosphate (cGMP) in penile smooth muscle, PT-141 acts upstream in the brain to initiate the neural outflow that eventually drives both psychogenic and reflexogenic erection. This distinction is clinically relevant because men with psychogenic erectile dysfunction or those whose vascular response to sildenafil is insufficient may still respond to centrally acting melanocortin agonism.

In females, MC4R activation in hypothalamic circuits is thought to increase sensitivity to sexual stimuli and reduce the central inhibitory tone that can suppress desire. The exact downstream signaling chain in women remains under active investigation, but the behavioral response in animal models and the clinical data supporting HSDD treatment both point to a meaningful role for hypothalamic melanocortin circuits in female sexual motivation.

PT-141 differs from its parent molecule melanotan II by the absence of significant MC1R activity, which reduces tanning side effects. The cyclic lactam structure also confers greater metabolic stability than linear peptide analogs, contributing to its measurable pharmacodynamic window following subcutaneous administration.

The research history of PT-141 spans roughly two decades and includes both preclinical mechanistic studies and multiple human clinical trials, culminating in regulatory approval. A 2003 article in the Annals of the New York Academy of Sciences provided an early summary of PT-141 as a melanocortin agonist for sexual dysfunction, framing the compound's origins in the melanotan II observation and outlining early trial rationale. A 2004 review in Current Opinion in Investigational Drugs from Palatin's team described the compound's profile and developmental trajectory.

A key human pharmacokinetic and pharmacodynamic study published in the International Journal of Impotence Research in 2004 evaluated subcutaneous PT-141 administration in healthy male subjects and in men who showed inadequate response to sildenafil. The study found dose-dependent erectile activity and characterized the compound's absorption and safety profile, establishing a foundation for subsequent dose selection in trials.

A 2005 study published in Urology examined co-administration of low intranasal doses of PT-141 with sildenafil in men with erectile dysfunction. Researchers found that combining the two agents produced an enhanced erectile response compared to sildenafil alone at the doses tested, suggesting potential for combination strategies in treatment-resistant patients. This work supported the concept that central and peripheral mechanisms of erection could be targeted synergistically.

Broader reviews of melanocortin peptide therapeutics, including a 2006 article in Peptides and a 2007 review in Current Topics in Medicinal Chemistry, placed PT-141 in historical context, cataloging the progression from α-MSH analogs through melanotan I and II to PT-141, and detailing clinical study designs across male and female populations. These reviews noted that female HSDD emerged as the clearest regulatory pathway given unmet medical need.

The pivotal trials for the FDA application enrolled premenopausal women with acquired, generalized HSDD. Published results from Phase 3 trials indicated that bremelanotide 1.75 mg administered subcutaneously approximately 45 minutes before sexual activity produced statistically significant improvements in satisfying sexual events and reductions in distress scores compared to placebo. Nausea was the most commonly reported adverse event, occurring in approximately 40% of bremelanotide-treated participants in the pivotal studies, compared to roughly 1% in placebo groups.

A 2025 narrative review in Expert Opinion on Pharmacotherapy revisited intravenous peptide approaches to erectile dysfunction, situating PT-141 alongside newer investigational agents and noting that its approval for HSDD had stimulated renewed interest in central melanocortin mechanisms for male indications as well. The human evidence base for PT-141 in males remains limited to Phase 2 data, and no large Phase 3 erectile dysfunction trial has been completed to date.

In a 2004 International Journal of Impotence Research study, subcutaneous doses ranging from 0.3 mg to 10 mg were evaluated in male subjects, with dose-dependent erectile responses observed. A 2005 Urology study tested intranasal PT-141 at low doses (approximately 7.5 mg intranasally) combined with sildenafil in men with erectile dysfunction. For the FDA-approved indication in premenopausal women with HSDD, the approved dose of bremelanotide is 1.75 mg administered as a single subcutaneous injection approximately 45 minutes before anticipated sexual activity, with a maximum of one dose per 24 hours as specified in the approved prescribing information.

PT-141's safety profile has been characterized across Phase 1, Phase 2, and Phase 3 clinical trials, with the most complete human data deriving from the pivotal HSDD trials that supported FDA approval. The most frequently reported adverse event in those trials was nausea, occurring in approximately 40% of participants receiving bremelanotide 1.75 mg subcutaneously, compared to approximately 1% in placebo-treated participants. Flushing, which typically manifests as facial warmth and redness, was the second most common adverse event.

Transient increases in blood pressure were observed in clinical studies. The prescribing information for Vyleesi notes that bremelanotide can cause a mean maximum decrease in systolic blood pressure of approximately 2 mmHg and a mean maximum increase of approximately 5 mmHg in some measurements depending on timing. Cardiovascular safety monitoring was therefore a component of the clinical program, and the drug is contraindicated in patients with known cardiovascular disease.

In the early male erectile dysfunction studies using subcutaneous doses up to 10 mg, nausea and flushing were also the predominant adverse events reported, with dose-dependent frequency. The intranasal formulation studied in 2005 was later discontinued in part due to concerns about greater variability in blood pressure responses, which contributed to Palatin's shift to subcutaneous administration.

Hyperpigmentation, a predictable consequence of melanocortin receptor activation, was observed in some participants with prolonged or high-dose exposure, though this was less prominent with PT-141 than with earlier analogs such as melanotan II due to reduced MC1R activity in the PT-141 structure.

Long-term safety data beyond one year remain limited. The approved labeling reflects this gap, noting that the effects of repeated use beyond the studied timeframes are not fully characterized. Independent use of PT-141 outside of medical supervision carries risks that cannot be fully quantified with available data, particularly regarding cardiovascular and gastrointestinal effects in unstudied populations.

PT-141, marketed as Vyleesi, received FDA approval in June 2019 for the treatment of acquired, generalized hypoactive sexual desire disorder in premenopausal women. This makes it one of only two FDA-approved pharmacological treatments for female sexual dysfunction, alongside flibanserin. The approval was based on two Phase 3 randomized controlled trials demonstrating statistically significant improvements in satisfying sexual events and distress scores.

Research interest continues in male sexual dysfunction applications. Phase 2 data in men with erectile dysfunction, including those who did not respond adequately to sildenafil, showed encouraging signals, but no Phase 3 erectile dysfunction trial has been completed. A 2025 review in Expert Opinion on Pharmacotherapy identified PT-141 as part of an emerging category of centrally acting peptide therapies for male sexual dysfunction.

Mechanistic researchers continue to explore the role of MC3R and MC4R signaling in sexual motivation circuits, using PT-141 as a pharmacological probe. Key evidence gaps include long-term safety data, efficacy data in postmenopausal women, and outcomes in populations with comorbid hormonal disorders.